Daratumumab Myeloma Trials

Darzalex^® is not chemotherapy. Darzalex^® is a monoclonal antibody that works in several ways. One way this monoclonal antibody works is by attaching itself to multiple myeloma cells in your body and directly killing them, and/or allowing your immune system to destroy them.

Darzalex^® targets and attaches to a protein called CD38, which is present on the surface of certain types of cells (eg, red blood cells) and is also present in high numbers on multiple myeloma cells. Since Darzalex^® targets the CD38 protein, it may also affect other cells with this protein on their surface.

SparkCures ID	51
Developed By	Janssen Research & Development
Brand Name	Darzalex^®
Generic Name	Daratumumab
Additional Names	CD38 mAb, HuMax-CD38
Treatment Classifications	Monoclonal Antibody
Treatment Targets	CD38
Tags	FDA Approved Published Results

All Clinical Trials

View all active clinical trials around the US.

Verified

Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/...

MAGNETISMM-5

View Trial

Verified

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in P...

EXCALIBER

View Trial

Verified

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, ...

MONUMENTAL-3

View Trial

Verified

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratum...

MAJESTEC-3

View Trial

Verified

Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma

CAMMA-1

View Trial

Verified

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (...

View Trial

Verified

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

View Trial

Verified

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

View Trial

Verified

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)

ADVANCE

View Trial

Verified

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

View Trial

Verified

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NEWLY DIAGNOSED DKRD

View Trial

Verified

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in...

CC-92480-MM-002

View Trial

Verified

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

View Trial

Verified

FT576 in Subjects With Multiple Myeloma

FT576

View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE ...

EQUATE

View Trial

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants Wi...

MAJESTEC-7

View Trial

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duratio...

DRAMMATIC

View Trial

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering ...

DETER-SMM

View Trial

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

MILESTONE

View Trial

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

REACH

View Trial

Study of Lenalidomide / Ixazomib / Dexamethasone / Daratumumab in Transplant-Ineligible Patients With Newly...

View Trial

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

View Trial

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

View Trial

Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients...

IBER-KDD

View Trial

A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in P...

View Trial

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

SELINEXOR

View Trial

DARA RVD For High Risk SMM

PRISM

View Trial

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refracto...

View Trial

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myelo...

D-CLAPD

View Trial

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

View Trial

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multip...

View Trial

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multipl...

SELINEXOR

View Trial

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating...

View Trial

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly Newly Diagnosed ...

View Trial

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

DARATUMUMAB

View Trial

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multip...

View Trial

Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...

View Trial

Myeloma-Developing Regimens Using Genomics

MYDRUG

View Trial

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple ...

GEN3014 (HEXABODY®-CD38)

View Trial

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

IINNOVATE-3

View Trial

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

IINNOVATE-2

View Trial

Home Based Daratumumab Administration for Patients With Multiple Myeloma

View Trial

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (COMMANDER)

COMMANDER

View Trial

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myelom...

IDEAL

View Trial

A Study Of TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma

TAK-981

View Trial

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in C...

ABBV-383

View Trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments f...

LINVOSELTAMAB

View Trial

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

MONUMENTAL-2

View Trial

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple My...

APG-2575

View Trial

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Verified